Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) EBT Margin: 2010-2025

Historic EBT Margin for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to -8.04%.

  • Anika Therapeutics' EBT Margin fell 914.00% to -8.04% in Q3 2025 from the same period last year, while for Sep 2025 it was -10.06%, marking a year-over-year decrease of 3607.00%. This contributed to the annual value of -3.40% for FY2024, which is 601.00% down from last year.
  • As of Q3 2025, Anika Therapeutics' EBT Margin stood at -8.04%, which was up 42.81% from -14.05% recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' EBT Margin ranged from a high of 23.93% in Q2 2021 and a low of -871.99% during Q4 2023.
  • Moreover, its 3-year median value for EBT Margin was -8.04% (2025), whereas its average is -88.92%.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by 57,992bps in 2022, then spiked by 86,782bps in 2024.
  • Quarterly analysis of 5 years shows Anika Therapeutics' EBT Margin stood at -18.54% in 2021, then plummeted by 57,992bps to -598.46% in 2022, then tumbled by 27,353bps to -871.99% in 2023, then surged by 86,782bps to -4.17% in 2024, then slumped by 914bps to -8.04% in 2025.
  • Its EBT Margin was -8.04% in Q3 2025, compared to -14.05% in Q2 2025 and -14.79% in Q1 2025.